Vor Biopharma raised a $110M Series B (crossover) to advance its lead engineered hematopoietic stem cell candidate, VOR33, into clinical trials for #AML in 1H 2021. 

Investors include RA Capital, Fidelity, Pagliuca, Alexandria, $PRTC, 5AM, $JNJ &amp; Osage.

https://t.co/KwqRdvOizx